Skip to main content
Fig. 2 | Journal of Experimental & Clinical Cancer Research

Fig. 2

From: CCDC6 and USP7 expression levels suggest novel treatment options in high-grade urothelial bladder cancer

Fig. 2

a J82 cells were pretreated with the vehicle (DMSO) or P5091 [8 μM] for 4 h and transfected with DR-GFP alone, as control, or together with I-SceI, for 48 h. The percentage of GFP positive cells, compared to controls, has been plotted on histograms representative of three independent experiments. Error bars indicate the standard error mean. Transfection efficacy has been plotted on the histograms shown on the right. b-e Survival fractions of J82, T24, 5637 and KU-19-19 cells treated with Olaparib, at the indicated doses, in presence or absence of P5091 [1.5 μM], for 144 h. Sensitivity to Olaparib, in presence or absence of P5091, was determined by a modified MTT assay (MTS), Cell Titer 96 AQueous One Solution assay, and expressed as IC50, i.e. the value that allows 50% of the inhibitory concentration. The IC50 values are expressed as mean ± the standard deviation. Statistical differences were determined by two-tailed Student’s t test. Statistical significance is displayed as: * p < 0.05; ** p < 0.01; *** p < 0.001

Back to article page